Civic Intelligence

Saras Cure

990EZ • Fiscal year 2021 • EIN 82-5445706

Jan 01, 2021 to Dec 31, 2021 • Filed on Nov 15, 2022

783 Stiles DriveCharleston, SC 29412

(843) 864-6760

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

70th percentile

0.03x

Higher debt load relative to assets than 70% of similar nonprofits.

2021 filings • 501(c)3 • <$500k nonprofits • Source year 2021

Liabilities / Revenue

73rd percentile

0.04x

Higher debt load relative to revenue than 73% of similar nonprofits.

2021 filings • 501(c)3 • <$500k nonprofits • Source year 2021

Net Margin

15th percentile

-33%

Higher net margin than 15% of similar nonprofits.

2021 filings • 501(c)3 • <$500k nonprofits • Source year 2021

Top Officer Pay

84th percentile

$19,500

Higher top officer pay than 84% of similar nonprofits.

Top officer pay equals 24.0% of source-year revenue.

2021 filings • 501(c)3 • <$500k nonprofits • Source year 2021

Asset Growth

18th percentile

-21%

Faster asset growth than 18% of similar nonprofits.

2021 filings • 501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Revenue Growth

17th percentile

-49%

Faster revenue growth than 17% of similar nonprofits.

2021 filings • 501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Assets

Down

$99,408

Down $26,152 (-21%) from 2020

Net Assets

Down

$96,240

Down $26,812 (-22%) from 2020

Liabilities

Up

$3,168

Up $660 (+26%) from 2020

Revenue

Down

$81,170

Down $77,048 (-49%) from 2020

Expenses

Up

$107,983

Up $12,732 (+13%) from 2020

Net Income

Down

-$26,813

Down $89,780 (-143%) from 2020

Historical Trend

Balance Sheet Trend

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$150K$100K$50K$0Assets 2018: $87,281Liabilities 2018: $0Net Assets 2018: $87,2812018Assets 2019: $62,110Liabilities 2019: $2,025Net Assets 2019: $60,0852019Assets 2020: $125,560Liabilities 2020: $2,508Net Assets 2020: $123,0522020Assets 2021: $99,408Liabilities 2021: $3,168Net Assets 2021: $96,2402021Assets 2022: $91,017Liabilities 2022: $0Net Assets 2022: $91,0172022Assets 2023: $64,774Liabilities 2023: $57Net Assets 2023: $64,7172023Assets 2024: $51,801Net Assets 2024: $51,8012024

Highlighted filing

2021

Assets$99,408
Liabilities$3,168
Net Assets$96,240

Operations Trend

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$200K$100K$0-$100KRevenue 2018: $140,900Expenses 2018: $53,619Net Income 2018: $87,2812018Revenue 2019: $148,825Expenses 2019: $176,021Net Income 2019: -$27,1962019Revenue 2020: $158,218Expenses 2020: $95,251Net Income 2020: $62,9672020Revenue 2021: $81,170Expenses 2021: $107,983Net Income 2021: -$26,8132021Revenue 2022: $99,906Expenses 2022: $105,129Net Income 2022: -$5,2232022Revenue 2023: $70,362Expenses 2023: $96,662Net Income 2023: -$26,3002023Revenue 2024: $91,784Expenses 2024: $104,700Net Income 2024: -$12,9162024

Highlighted filing

2021

Revenue$81,170
Expenses$107,983
Net Income-$26,813
Jump To
Filing Snapshot
Filing Period
Jan 1, 2021 to Dec 31, 2021
Signed
Nov 15, 2022
Return Version
2021v4.0
Gross Receipts
$81,170
Mission and Program Overview

Mission

The mission of sara's cure is to make clear cell sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact change and strive toward the cure.

The mission of sara's cure is to make clear cell sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact change and strive towards the cure.

Program Services

DescriptionGrantsExpenses
SARA'S CURE IS THE ONLY NON-PROFIT REPRESENTING CLEAR CELL SARCOMA IN THE USA BUT WE COLLABORATE WITH OTHERS THROUGHOUT THE WORLD TO ENSURE OUR WORK IS EFFICIENT, MEANINGFUL AND IMPACTFUL TO THE CCS FAMILY OF PATIENTS AND OUR CHAMPION CLINICIANS. THROUGHOUT 2021 WE HAVE CONTINUED FUNDING REPURPOSED DRUG TESTING BY WORKING WITH OUR MEDICAL ADVISORS AND THEIR LABS. OUR EXECUTIVE DIRECTOR SERVES ON AN FDA REPURPOSED DRUG TESTING TASK FORCE THAT MEETS MONTHLY. THIS STRATEGIC INVOLVEMENT WITH KEY LEADERS ENSURES THAT THE TIME AND MONEY SPENT IS PUT TO ITS HIGHEST AND BEST USE. IN NOVEMBER 2021 THE FIRST OF ITS KIND PHASE I/II CCS TRIAL OPENED. THIS WAS DONE IN COLLABORATION WITH RAFAEL (NOW CORNERSTONE PHARMA), THE FDA, AND MOST IMPORTANT THE CCS FAMILY OF PATIENTS. WE PARTNERED TO DO THIS BY AGREEING TO PROVIDE FINANCIAL SUPPORT TO PATIENTS IN THE FORM OF TRAVEL REIMBURSEMENT TO HELP PATIENTS GET TO TRIAL LOCATIONS. WE HIRED THE NATIONAL ORGANIZATION OF RARE DISORDERS TO MANAGE THE DISBURSEMENT OF FUNDS TO THE CCS PATIENTS DIRECTLY. WE HAVE HELPED SEVERAL PATIENTS TO DATE. THE CLINICAL TRIAL IS ONGOING. WE CONTINUE TO BUILD THE REGISTRY WITH NORD AND FINALIZED THE DATA DICTIONARY IN DEC 2021. WE CONTINUE TO SUPPORT PATIENTS THROUGH REFERRALS TO SARCOMA CENTERS OF EXCELLENCE AND TO THE DOCTORS THAT CHAMPION THE CCS RESEARCH WHO WORK WITH US TO SUPPORT OUR MISSION. WE ATTENDED THE WORLD ORPHAN DRUG CONGRESS IN AUGUST 2021 AND HAD A CCS FATHER/BOARD MEMBER ATTEND AS WELL AS OUR EXECUTIVE AND SCIENTIFIC DIRECTORS WHO ALSO ATTENDED THE NORD AND CTOS SARCOMA CONFERENCES VIRTUALLY. THE CCS FAMILY OF PATIENTS CONTINUES TO BE THE DRIVING FORCE WITHIN THE ORGANIZATION AND HAS BEEN CRITICAL TO ACTIVELY AND FINANCIALLY SUPPORTING THE WORK WE DO BY PARTICIPATING IN FOCUS GROUPS, PROVIDING PATIENT EXPERIENCE INPUT AND HOSTING FUNDRAISERS IN THEIR COMMUNITIES AROUND THE GLOBE INCLUDING ONLINE EVENTS AND FACEBOOK FUNDRAISERS.--
Compensation and Service Providers

Employees

NameTitleFull / Part TimeBaseOtherTotal
LENNIE WOODSExecutive DiFT$19,500-$19,500
KELLY ARGRAVES PHDScientific DPT$12,000-$12,000
JENAE HELLERBoard Member-$0--
DRU WILLIAMSBoard Member-$0--
DAWN JUDDTreasurer-$0--
DENNY WOODSBoard Member-$0--
BRUCE NEWBYBoard Member-$0--
NANETTE DETURKBoard Member-$0--
EVAN BARNESBoard Member-$0--
Filing and Contact Details

Filer

Filer Name
SARA'S CURE
EIN
82-5445706
Phone
8438646760
Address
783 STILES DRIVE, CHARLESTON, SC 29412

Signing Officer

Name
Dawn Judd
Title
Treasurer
Phone
8438646760
Signed
2022-11-15
Discuss with paid preparer
Yes

Preparer

Firm
Hinske & Clarey LLC
Address
109 WAPPOO CREEK DR STE 1A, CHARLESTON, SC 29412-2166
Preparer
Nichole V Hinske CPA
Phone
8437620452
Supplemental Narrative

Additional Explanations

Form 990-ez, Part I, Line 16

Expenses advertising and website 8,502 marketing materials 2,938 bank & credit card fees 171 supplies 571 travel 6,232 repurpose drug testing 3,000 total 21,414

Form 990-ez, Part II, Line 26

CREDIT CARD 2,508 3,168

Form 990-ez, Part III

The mission of sara's cure is to make clear cell sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact change and strive towards the cure.

Form 990-ez, Part III, Line 28

Sara's cure is the only non-profit representing clear cell sarcoma in the usa but we collaborate with others throughout the world to ensure our work is efficient, meaningful and impactful to the ccs family of patients and our champion clinicians. Throughout 2021 we have continued funding repurposed drug testing by working with our medical advisors and their labs. Our executive director serves on an fda repurposed drug testing task force that meets monthly. This strategic involvement with key leaders ensures that the time and money spent is put to its highest and best use. In november 2021 the first of its kind phase i/ii ccs trial opened. This was done in collaboration with rafael (now cornerstone pharma), the fda, and most important the ccs family of patients. We partnered to do this by agreeing to provide financial support to patients in the form of travel reimbursement to help patients get to trial locations. We hired the national organization of rare disorders to manage the disbursement of funds to the ccs patients directly. We have helped several patients to date. The clinical trial is ongoing. We continue to build the registry with nord and finalized the data dictionary in dec 2021. We continue to support patients through referrals to sarcoma centers of excellence and to the doctors that champion the ccs research who work with us to support our mission. We attended the world orphan drug congress in august 2021 and had a ccs father/board member attend as well as our executive and scientific directors who also attended the nord and ctos sarcoma conferences virtually. The ccs family of patients continues to be the driving force within the organization and has been critical to actively and financially supporting the work we do by participating in focus groups, providing patient experience input and hosting fundraisers in their communities around the globe including online events and facebook fundraisers.

Raw XML Appendix171 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0DAWN JUDD
IRS990EZ/BooksInCareOfDetail/PhoneNum08438646760
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt01166 MARINER DRIVE
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0CHARLESTON
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0SC
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd029412
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt0125561
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt099408
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt080588
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-26813
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt084535
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0125561
IRS990EZ/Form990TotalAssetsGrp/EOYAmt099408
IRS990EZ/FundraisingGrossIncomeAmt0580
IRS990EZ/GrossReceiptsAmt081170
IRS990EZ/InfoInScheduleOPartIIIInd0X
IRS990EZ/InfoInScheduleOPartIIInd0X
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt02
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0123053
IRS990EZ/NetAssetsOrFundBalancesEOYAmt096240
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0123053
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt096240
IRS990EZ/OccupancyRentUtltsAndMaintAmt0764
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt040.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt110.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt21.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt31.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt41.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt51.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt61.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt71.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt81.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt019500
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt112000
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt70
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt80
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0LENNIE WOODS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1KELLY ARGRAVES PHD
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2JENAE HELLER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3DRU WILLIAMS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4DAWN JUDD
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5DENNY WOODS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6BRUCE NEWBY
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm7NANETTE DETURK
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm8EVAN BARNES
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0EXECUTIVE DI
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1SCIENTIFIC D
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4TREASURER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt7BOARD MEMBER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt8BOARD MEMBER
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt021414
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0THE MISSION OF SARA'S CURE IS TO MAKE CLEAR CELL SARCOMA SURVIVABLE THROUGH EDUCATION AND SCIENTIFIC RESEARCH WHILE ENSURING ALL PATIENTS AND CAREGIVERS IMPACTED HAVE A VOICE AND PLATFORM TO ENACT CHANGE AND STRIVE TOWARDS THE CURE.
IRS990EZ/PrintingPublicationsPostageAmt01270
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0SARA'S CURE IS THE ONLY NON-PROFIT REPRESENTING CLEAR CELL SARCOMA IN THE USA BUT WE COLLABORATE WITH OTHERS THROUGHOUT THE WORLD TO ENSURE OUR WORK IS EFFICIENT, MEANINGFUL AND IMPACTFUL TO THE CCS FAMILY OF PATIENTS AND OUR CHAMPION CLINICIANS. THROUGHOUT 2021 WE HAVE CONTINUED FUNDING REPURPOSED DRUG TESTING BY WORKING WITH OUR MEDICAL ADVISORS AND THEIR LABS. OUR EXECUTIVE DIRECTOR SERVES ON AN FDA REPURPOSED DRUG TESTING TASK FORCE THAT MEETS MONTHLY. THIS STRATEGIC INVOLVEMENT WITH KEY LEADERS ENSURES THAT THE TIME AND MONEY SPENT IS PUT TO ITS HIGHEST AND BEST USE. IN NOVEMBER 2021 THE FIRST OF ITS KIND PHASE I/II CCS TRIAL OPENED. THIS WAS DONE IN COLLABORATION WITH RAFAEL (NOW CORNERSTONE PHARMA), THE FDA, AND MOST IMPORTANT THE CCS FAMILY OF PATIENTS. WE PARTNERED TO DO THIS BY AGREEING TO PROVIDE FINANCIAL SUPPORT TO PATIENTS IN THE FORM OF TRAVEL REIMBURSEMENT TO HELP PATIENTS GET TO TRIAL LOCATIONS. WE HIRED THE NATIONAL ORGANIZATION OF RARE DISORDERS TO MANAGE THE DISBURSEMENT OF FUNDS TO THE CCS PATIENTS DIRECTLY. WE HAVE HELPED SEVERAL PATIENTS TO DATE. THE CLINICAL TRIAL IS ONGOING. WE CONTINUE TO BUILD THE REGISTRY WITH NORD AND FINALIZED THE DATA DICTIONARY IN DEC 2021. WE CONTINUE TO SUPPORT PATIENTS THROUGH REFERRALS TO SARCOMA CENTERS OF EXCELLENCE AND TO THE DOCTORS THAT CHAMPION THE CCS RESEARCH WHO WORK WITH US TO SUPPORT OUR MISSION. WE ATTENDED THE WORLD ORPHAN DRUG CONGRESS IN AUGUST 2021 AND HAD A CCS FATHER/BOARD MEMBER ATTEND AS WELL AS OUR EXECUTIVE AND SCIENTIFIC DIRECTORS WHO ALSO ATTENDED THE NORD AND CTOS SARCOMA CONFERENCES VIRTUALLY. THE CCS FAMILY OF PATIENTS CONTINUES TO BE THE DRIVING FORCE WITHIN THE ORGANIZATION AND HAS BEEN CRITICAL TO ACTIVELY AND FINANCIALLY SUPPORTING THE WORK WE DO BY PARTICIPATING IN FOCUS GROUPS, PROVIDING PATIENT EXPERIENCE INPUT AND HOSTING FUNDRAISERS IN THEIR COMMUNITIES AROUND THE GLOBE INCLUDING ONLINE EVENTS AND FACEBOOK FUNDRAISERS.
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsNetIncomeLossAmt0580
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0SC
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt02508
IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt03168
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TotalExpensesAmt0107983
IRS990EZ/TotalRevenueAmt081170
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationCorpInd0X
IRS990EZ/WebsiteAddressTxt0WWW.SARASCURE.ORG
IRS990ScheduleA/First5Years509Ind0X
IRS990ScheduleA/Form990ScheduleAPartVIGrp/ExplanationTxt0OTHER 21,713
IRS990ScheduleA/Form990ScheduleAPartVIGrp/FormAndLineReferenceDesc0PART III, LINE 12
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearAmt080588
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus1YearAmt097218
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus2YearsAmt0147312
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/CurrentTaxYearMinus3YearsAmt0120700
IRS990ScheduleA/GiftsGrantsContrisRcvd509Grp/TotalAmt0445818
IRS990ScheduleA/GrossReceiptsAdmissionsGrp/CurrentTaxYearAmt0582
IRS990ScheduleA/GrossReceiptsAdmissionsGrp/CurrentTaxYearMinus1YearAmt061000
IRS990ScheduleA/GrossReceiptsAdmissionsGrp/TotalAmt061582
IRS990ScheduleA/OtherIncome509Grp/CurrentTaxYearMinus2YearsAmt01513
IRS990ScheduleA/OtherIncome509Grp/CurrentTaxYearMinus3YearsAmt020200
IRS990ScheduleA/OtherIncome509Grp/TotalAmt021713
IRS990ScheduleA/PubliclySupportedOrg509a2Ind0X
IRS990ScheduleA/PublicSupportTotal509Amt0507400
IRS990ScheduleA/Total509Grp/CurrentTaxYearAmt081170
IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus1YearAmt0158218
IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus2YearsAmt0147312
IRS990ScheduleA/Total509Grp/CurrentTaxYearMinus3YearsAmt0120700
IRS990ScheduleA/Total509Grp/TotalAmt0507400
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearAmt081170
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus1YearAmt0158218
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus2YearsAmt0148825
IRS990ScheduleA/TotalSupportCalendarYearGrp/CurrentTaxYearMinus3YearsAmt0140900
IRS990ScheduleA/TotalSupportCalendarYearGrp/TotalAmt0529113
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0EXPENSES ADVERTISING AND WEBSITE 8,502 MARKETING MATERIALS 2,938 BANK & CREDIT CARD FEES 171 SUPPLIES 571 TRAVEL 6,232 REPURPOSE DRUG TESTING 3,000 TOTAL 21,414
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1CREDIT CARD 2,508 3,168
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2THE MISSION OF SARA'S CURE IS TO MAKE CLEAR CELL SARCOMA SURVIVABLE THROUGH EDUCATION AND SCIENTIFIC RESEARCH WHILE ENSURING ALL PATIENTS AND CAREGIVERS IMPACTED HAVE A VOICE AND PLATFORM TO ENACT CHANGE AND STRIVE TOWARDS THE CURE.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3SARA'S CURE IS THE ONLY NON-PROFIT REPRESENTING CLEAR CELL SARCOMA IN THE USA BUT WE COLLABORATE WITH OTHERS THROUGHOUT THE WORLD TO ENSURE OUR WORK IS EFFICIENT, MEANINGFUL AND IMPACTFUL TO THE CCS FAMILY OF PATIENTS AND OUR CHAMPION CLINICIANS. THROUGHOUT 2021 WE HAVE CONTINUED FUNDING REPURPOSED DRUG TESTING BY WORKING WITH OUR MEDICAL ADVISORS AND THEIR LABS. OUR EXECUTIVE DIRECTOR SERVES ON AN FDA REPURPOSED DRUG TESTING TASK FORCE THAT MEETS MONTHLY. THIS STRATEGIC INVOLVEMENT WITH KEY LEADERS ENSURES THAT THE TIME AND MONEY SPENT IS PUT TO ITS HIGHEST AND BEST USE. IN NOVEMBER 2021 THE FIRST OF ITS KIND PHASE I/II CCS TRIAL OPENED. THIS WAS DONE IN COLLABORATION WITH RAFAEL (NOW CORNERSTONE PHARMA), THE FDA, AND MOST IMPORTANT THE CCS FAMILY OF PATIENTS. WE PARTNERED TO DO THIS BY AGREEING TO PROVIDE FINANCIAL SUPPORT TO PATIENTS IN THE FORM OF TRAVEL REIMBURSEMENT TO HELP PATIENTS GET TO TRIAL LOCATIONS. WE HIRED THE NATIONAL ORGANIZATION OF RARE DISORDERS TO MANAGE THE DISBURSEMENT OF FUNDS TO THE CCS PATIENTS DIRECTLY. WE HAVE HELPED SEVERAL PATIENTS TO DATE. THE CLINICAL TRIAL IS ONGOING. WE CONTINUE TO BUILD THE REGISTRY WITH NORD AND FINALIZED THE DATA DICTIONARY IN DEC 2021. WE CONTINUE TO SUPPORT PATIENTS THROUGH REFERRALS TO SARCOMA CENTERS OF EXCELLENCE AND TO THE DOCTORS THAT CHAMPION THE CCS RESEARCH WHO WORK WITH US TO SUPPORT OUR MISSION. WE ATTENDED THE WORLD ORPHAN DRUG CONGRESS IN AUGUST 2021 AND HAD A CCS FATHER/BOARD MEMBER ATTEND AS WELL AS OUR EXECUTIVE AND SCIENTIFIC DIRECTORS WHO ALSO ATTENDED THE NORD AND CTOS SARCOMA CONFERENCES VIRTUALLY. THE CCS FAMILY OF PATIENTS CONTINUES TO BE THE DRIVING FORCE WITHIN THE ORGANIZATION AND HAS BEEN CRITICAL TO ACTIVELY AND FINANCIALLY SUPPORTING THE WORK WE DO BY PARTICIPATING IN FOCUS GROUPS, PROVIDING PATIENT EXPERIENCE INPUT AND HOSTING FUNDRAISERS IN THEIR COMMUNITIES AROUND THE GLOBE INCLUDING ONLINE EVENTS AND FACEBOOK FUNDRAISERS.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0FORM 990-EZ, PART I, LINE 16
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1FORM 990-EZ, PART II, LINE 26
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2FORM 990-EZ, PART III
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3FORM 990-EZ, PART III, LINE 28
TransferPrsnlBnftContractsDecl/DeclarationDesc0THE ORGANIZTION DID NOT, DURING THE YEAR, RECEIVE ANY FUNDS, DORECTLY OR INDIRECTLY, TO PAY PREMIUMS ON A PERSONAL BENEFIT CONTRACT.
ReturnHeader/BuildTS02022-09-23 18:48:47Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0DAWN JUDD
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0TREASURER
ReturnHeader/BusinessOfficerGrp/PhoneNum08438646760
ReturnHeader/BusinessOfficerGrp/SignatureDt02022-11-15
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0SARA'S CURE
ReturnHeader/Filer/BusinessName/BusinessNameLine2Txt0CLEAR CELL SARCOMA FOUNDATION
ReturnHeader/Filer/BusinessNameControlTxt0SARA
ReturnHeader/Filer/EIN0825445706
ReturnHeader/Filer/PhoneNum08438646760
ReturnHeader/Filer/USAddress/AddressLine1Txt0783 STILES DRIVE
ReturnHeader/Filer/USAddress/CityNm0CHARLESTON
ReturnHeader/Filer/USAddress/StateAbbreviationCd0SC
ReturnHeader/Filer/USAddress/ZIPCd029412
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0271340692
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0HINSKE & CLAREY LLC
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt0109 WAPPOO CREEK DR STE 1A
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0CHARLESTON
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0SC
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd0294122166
ReturnHeader/PreparerPersonGrp/PhoneNum08437620452
ReturnHeader/PreparerPersonGrp/PreparationDt02022-11-15
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0NICHOLE V HINSKE CPA
ReturnHeader/ReturnTs02022-11-15T09:43:26-05:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm0DAWN
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm0JUDD
ReturnHeader/TaxPeriodBeginDt02021-01-01
ReturnHeader/TaxPeriodEndDt02021-12-31
ReturnHeader/TaxYr02021

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings